The Frontier of Melanoma Treatment: Defeating Immunotherapy Resistance—A Systematic Review
Authors:
- Kamila MozgaKMKamila Mozga
- Olga SynowieckaOSOlga Synowiecka
- Igor RydzykIRIgor Rydzyk
- Anna MarekAMAnna Marek
- Ewelina WieczorekEWEwelina Wieczorek
- Alicja PetniakAPAlicja Petniak
- Paulina Gil-KulikPGPaulina Gil-Kulik
Open Access
- 1 January 2026
- journal article
- review article
- Published by Tech Science Press in Oncology Research
- Vol. 34 (2) , 1-10
Abstract
Objectives: Immunotherapy based on immune checkpoint blockade (ICB) has become a key treatment for melanoma. However, the increasing number of cases of melanoma resistant to immunotherapy highlights the need to develop methods to overcome this resistance. This study aims to collect the most recent information on melanoma immunotherapy, discuss potential strategies to overcome resistance to immunotherapy, and identify areas that require further analysis. Methods: To achieve this goal, scientific publications from 2021–2024 available in PubMed and Google Scholar databases were analyzed. The databases were searched using the following terms: “melanoma”, “immunotherapy”, “Immune Checkpoint Blockade”, and “immunoresistance”. Results: The results of preclinical and early-stage clinical research indicate the potential application of tank-binding kinase 1 (TBK-1), fecal microbiota transplant (FMT), Toll-like Receptor 9 (TLR9), lipid nanoparticles (LNPs) containing a stimulator of an interferon gene agonist (STING), BRAF inhibitors, Lymphocyte Activation Gene (LAG-3), T-Cell Immunoglobulin and ITIM Domain (TIGIT), and oncolytic viruses (OVs) as potential methods to enhance melanoma sensitivity to ICB. Discussion: To optimize immunotherapy, further research is needed to determine the detailed mechanisms of action, safety profiles, tolerability, and precise patient selection criteria for methods capable of overcoming melanoma’s immunoresistanceKeywords
This publication has 47 references indexed in Scilit:
- Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of actionEuropean Journal of Immunology, 2021
- Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini reviewBiochimica et Biophysica Acta (BBA) - General Subjects, 2021
- Value of PD-L1, PD-1, and CTLA-4 Expression in the Clinical Practice as Predictors of Response to Nivolumab and Ipilimumab in Monotherapy in Patients With Advanced Stage MelanomaThe American Journal of Dermatopathology, 2020
- Drug tolerance to target therapy in melanoma revealed at single cell level: What next?Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2020
- Systemic Therapy for Melanoma: ASCO GuidelineJournal of Clinical Oncology, 2020
- Toll-Like Receptor 9 Agonists in CancerOncoTargets and Therapy, 2020
- The Specific IKKε/TBK1 Inhibitor Amlexanox Suppresses Human Melanoma by the Inhibition of Autophagy, NF-κB and MAP Kinase PathwaysInternational Journal of Molecular Sciences, 2020
- The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary PathwayArchives of Pathology & Laboratory Medicine, 2020
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune RegulationImmunity, 2016